YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)

Tamoxifen Increases Tumor Growth in Some Breast Cancer Patients

Dec 4, 2008 | Parker Waichman Alonso LLP

Tamoxifen, a drug routinely given to breast cancer patients, could actually increase tumor growth in certain patients, a new study has found.  The authors of the study, which was published in the journal Breast Cancer Research, said their work could eventually lead to tests that could screen out patients who might be endangered by taking tamoxifen.

According to the National Cancer Institute website, Tamoxifen has been used for more than 30 years to treat breast cancer in women and men.  Tamoxifen interferes with the activity of estrogen, a female hormone. Estrogen can promote the development of cancer in the breast. Tamoxifen is approved by the U.S. Food and Drug Administration (FDA) for the prevention of breast cancer and for the treatment of breast cancer, as well as other types of cancer.

According to Reuters.com, tamoxifen is given to most patients for five years after they are diagnosed with breast cancer to prevent the disease from returning.  However, some develop resistance, which means their tumor is more likely to recur. Last month, a British team identified a called Pax2  which contributed to the development of such resistance, Reuters said.

According to this latest tamoxifen study, use of drugs like tamoxifen in patients with low levels of another protein - E-cadherin - may promote more harmful cancer cell behavior. The E-cadherin protein makes cells stick together. In their experiments, researchers from Cardiff University found  that when the protein was at reduced levels, tamoxifen caused cancer cells to move around much more aggressively.  This activity can lead to tumor growth, they said.

The researchers said that the next stage of their work would be to determine an actual level of the protein that would cause tamoxifen to fail.  Further research could lead to the development of screening tests to identify breast cancer patients who should be given alternatives to drugs like tamoxifen.

Tamoxifen
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Bad Med
 
 

News Feeds

WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Social Security Disability | Contact
Statement of Clients' Rights | Site Map | Drug Injury Search | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome | Florida Personal Injury Law Firm

© 2002-2009 YourLawyer.com®. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News